Living Cell Technologies is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which use naturally occurring cells to restore function.

The business

- LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, and operations based in New Zealand.
- LCT is developing NTCELL® for the treatment of neurodegenerative diseases.

Product pipeline and key milestones

- In June 2015 LCT completed a Phase I/IIa clinical study of NTCELL in Parkinson’s disease. The study met the primary endpoint of safety. NTCELL also improved clinical features of Parkinson’s in the four patients studied.
- A Phase IIb study commenced in March 2016. Upon successful completion, the company intends to apply for provisional consent to treat paying patients in New Zealand in 2017.
- LCT is also investigating applications for NTCELL in other neurodegenerative conditions, including Huntington’s, Alzheimer’s and motor neurone diseases.

The science

- LCT’s product pipeline consists of cell therapies developed from cells sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands.
- LCT’s proprietary technology, IMMUPEL™, coats cells with protective capsules that prevent them from being attacked by the patient’s immune system. This allows the use of cell therapies without the need for co-treatment with drugs that suppress the immune system, which often have negative side effects.

Leadership

- CEO Dr Ken Taylor joined LCT in February 2014. Prior to joining LCT he had a prestigious international career in both academia and business including many years with Roche.
NTCELL®

- NTCELL is a cell therapy with the potential to halt disease progression in people with Parkinson’s disease.
- It is estimated that more than 7 million people worldwide have Parkinson’s disease.
- The global market for the current standard treatment for Parkinson’s disease – dopamine replacement – is approximately A$2 billion per annum.
- The Phase I/IIa clinical study of NTCELL showed it was safe and well tolerated.
- At 58 weeks post-implant, NTCELL reversed the progression of Parkinson’s disease, as measured by validated neurological rating scales and questionnaires, by 3-4 years.
- A Phase IIb clinical study commenced in March 2016. The primary endpoint will address the efficacy of NTCELL as a treatment for Parkinson’s disease.
- NTCELL has also demonstrated a powerful ability to regenerate damaged tissue and restore function in preclinical studies of other neurodegenerative diseases.

Joint venture with OPF

- In 2011, LCT formed the New Zealand 50:50 joint venture company Diatranz Otsuka Limited (DOL) in partnership with Otsuka Pharmaceutical Factory, Inc. (OPF) to accelerate the development of DIABECELL®, a cell therapy which, in clinical trials, has been shown to significantly improve some of the symptoms of type 1 diabetes.
- DOL has licenced OPF to use DIABECELL in the United States and Japan and OPF is developing an improved product in the United States. DOL has the right to commercialise the US product in the rest of the world.
- For more information visit: www.dolglobal.com.